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Abstract
Background: Due to few paediatric drug safety studies, knowledge on risks of drug treatment in
children is limited. The knowledge needs to be increased to make proper risk-benefit analyses
possible when treating paediatric patients with drugs. The aim of the present study was to
investigate drug groups commonly used in children concerning type and frequency of individual case
safety reports in children.
Methods: Number and type of individual case safety reports in the 30 groups of drugs (5th level
ATC-code) most sold (number of defined daily doses) in outpatient treatment to children (<15
years old) during 2005 were obtained. Descriptive analyses of the adverse drug reactions reported
in children were performed.
Results: The number of individual case safety reports per million defined daily doses in children
varied in the groups of drug between 0 and 24. The largest number was found in the drug group
R03DC, the leukotriene receptor antagonist montelukast; the majority of the children being <5
years old and experiencing psychiatric adverse drug reactions.
Conclusion: The number of individual case safety reports per million defined daily doses varies in
different groups of drugs. A possible signal for montelukast and psychiatric adverse drug reactions
was found, which should be further explored.
Background
Adverse drug reactions (ADRs) are a major health care
problem. ADRs cause hospital care in both adults [1-3]
and children [4]. Moreover, drug-related deaths have been
reported for children [5,6]. Consequently, a risk-benefit
analysis of drug treatment is essential in most patient con-
sultations including paediatric patients. This implies
access of adequate knowledge on both these parameters.
Due to few paediatric drug safety studies, knowledge on
risks in children is limited. At registration, little informa-
tion on ADRs in children is available since many drugs
have not been tested in children [7]. Off-label use of drugs
in children results in questions to drug information cen-
tres [8] and has been reported to be extensive [9-11],
reported to result in an increased risk of ADRs [9]. Risk-
benefit analyses of drugs for children are therefore
dependent on observations of ADRs and effects from clin-
ical use.
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Spontaneous reporting of ADRs is an important method
for detection of signals, which is one aim of pharmacovig-
ilance. An ADR signal is defined as a possible relationship
between an adverse event and a drug, the relationship
being unknown or incompletely documented previously.
In Sweden, physicians, dentists and nurses are obliged to
report (i) serious ADRs, (ii) ADRs not mentioned in the
SPC, (iii) ADRs related to the use of new drugs (≤ 2 years
on the market) except those labelled as common in the
summary of product characteristics (SPC), and (iv) ADRs
which incidence seems to increase. (MPA Code of Stat-
utes, 2006 [12]). An individual case safety report (ICSR)
can involve several ADRs. All ICSRs are reviewed and clas-
sified by trained nurses and physicians according to the
WHO Collaborating Centre for International Drug Moni-
toring instructions concerning e.g. seriousness of the ADR
before entered in the Swedish database for ADRs
(SWEDIS). A serious ADR is defined as any untoward
medical occurrence that at any dose: (i) results in death,
(ii) requires inpatient hospitalisation or prolongation of
existing hospitalisation, (iii) results in persistent or signif-
icant disability/incapacity or (iv) is life-threatening. A seri-
ous drawback of the spontaneous reporting system is that
the number of ICSRs is small in proportion to incidence
of ADRs [13,14].
The aim of the present study was to investigate drug
groups commonly used in children concerning the type
and frequency of ICSRs in children.
Methods
Apoteket AB has monopoly of prescription drug sales in
Sweden. A national prescription register (Xplain) was
established in the late 1990s to improve possibilities for
drug utilization studies. Data on age, sex and residential
area of the patient, as well as information on the pre-
scriber and the drug dispensed [e.g. number of defined
daily doses (DDD) and costs] are routinely gathered when
prescriptions are dispensed at Swedish pharmacies. In the
present study, Xplain was used to obtain the 30 groups of
drugs (5th level ATC-code) most sold [number of defined
daily doses (DDDs)] in outpatient treatment to children
(<15 years old) during January – December 2005 in Swe-
den. Within every group of drugs, ICSRs reported in chil-
dren to SWEDIS during the same period were acquired.
The number of ICSRs per million DDD in children was
calculated. For comparison, the corresponding number of
ICSRs per million DDD in adults (≥15 years old) was cal-
culated. The ICSRs including ADRs in foetus/children to
women who took the actual medicine were excluded. Vac-
cine reports were excluded, since no figures on DDD were
available.
Results
In 19 of the 30 most sold groups of drugs in children, at
least one ICSR was found (table 1). Totally 60 ICSRs were
found. The number of ICSRs per million DDD in children
varied in the groups of drug between 0 and 24. The largest
number was found in the drug group R03DC, leukotriene
receptor antagonists, the ADRs being described in table 2.
The second largest number of ICSRs was found in the drug
group centrally acting sympathomimetics. These reports
concerned children 7 – 12 years old, experiencing ADRs
during treatment with methylphenidate (n = 10) and ato-
moxetine (n = 2). ADRs reported more than once were
gastro-intestinal (n = 6), skin (n = 4), body as a whole –
general (n = 4), neurologic (n = 3), psychiatric (n = 3) and
cardiovascular (n = 3) disorders, according to the WHO
adverse reaction terminology preferred term. None of the
ICSRs were classified as serious.
Three ICSRs were classified as serious ADRs according to
the WHO definition. These reports concerned R05FA
Opium derivatives and expectorants [ethylmorhpine
(pancreatitis)], R06AX Other antihistamines for systemic
use [desloratadine (fatigue, xerostomia, nausea, abdomi-
nal pain)] and R03AC Selective beta-2-adrenoreceptor
agonists [terbutaline (vomiting)].
Discussion
ICSRs were present in 19 of the 30 most commonly used
drug groups in children. The number of ICSRs varied
between the groups of drugs, the two most reported drug
groups being the leukotriene receptor antagonists and
centrally acting sympathomimetics. The reporting of new
drugs should be expected to be larger compared with old
drugs, according to the Swedish instructions concerning
ADR reporting. The leukotriene receptor antagonist mon-
telukast was registered in 1998. Consequently, no extra
attention to ADRs during montelukast treatment was
demanded in 2005. Centrally acting sympathomimetics,
on the other hand, were introduced later and the number
of ICSRs may be influenced by the increased focus on this
drug group. Another explanation for increased reporting
rates for certain drug groups may be media attention.
ADRs during treatment with montelukast seem to occur
predominantly in small children, the majority in the
present study being <5 years old. In the SPC of montelu-
kast, nightmares and sleep disorders as well as aggressive-
ness are labelled as scarce ADRs. Anxiety, the diagnosis in
two ICSRs in the present study, is not labelled in the SPC.
The number of paediatric patients being reported to expe-
rience these psychiatric symptoms in the present study is
quite large and may thus be a signal, worthwhile to
explore further. Additional studies are needed to confirm
or contradict the signal.BMC Clinical Pharmacology 2008, 8:1 http://www.biomedcentral.com/1472-6904/8/1
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Table 1: ICSRs in children (<15 years old) and adults (≥15 years old) during 2005.
Children Adults
ATC code Name of group ICSR (n) Serious 
ADR (n)
Million 
DDD (n)
ICSR per 
million DDD 
(95% CI)
ICSR (n) Serious 
ADR (n)
Million 
DDD (n)
ICSR per 
million DDD 
(95% CI)
R03DC Leukotriene 
receptor 
antagonists
16 0 0.7 24 (13.6 – 38.6) 7 0 5.2 1.4 (0.5 – 2.8)
N06BA Centrally acting 
sympathomimetics
12 0 1.5 7.8 (4.0 – 13.6) 15 2 2.6 5.7 (3.2 – 9.5)
H02AB Glucocorticoids 3 0 0.7 4.5 (0.9 – 13.0) 31 21 32 1.0 (0.7 – 1.4)
H01BA Vasopressin and 
analogues
3 0 1.1 2.8 (0.6 – 8.2) 5 2 1.3 3.9 (1.3 – 9.2)
N03AX Other 
antiepileptics
1 0 0.4 2.4 (0.1 – 13.1) 58 19 9.7 6.0 (4.5 – 7.7)
R03CC Selective beta-2-
adrenoreceptor 
agonists
1 0 0.4 2.3 (0.1 – 12.6) 1 1 1.4 0.7 (0.02–3.9)
J01CA Penicillins with 
extended 
spectrum
1 0 0.5 2.1 (0.1 – 11.5) 12 3 3.9 3.1 (1.6 – 5.4)
R05FA Opium derivatives 
and expectorants
1 1 0.5 2.0 (0.1 – 11.4) 1 0 11 0.1 (0.002 – 0.5)
J01CE Beta-lactamase 
sensitive penicillins
3 0 1.6 1.8 (0.4 – 5.3) 14 5 11 1.3 (0.7 – 2.1)
A10AE Insulins and 
analogues. long-
acting
1 0 0.7 1.5 (0.04–8.5) 7 2 11 0.6 (0.3 – 1.3)
R06AX Other 
antihistamines for 
systemic use
5 1 3.4 1.5 (0.5 – 3.5) 14 3 31 0.5 (0.3 – 0.8)
H01AC Somatropin and 
somatropin 
agonists
1 0 0.8 1.3 (0.03–7.1) 2 0 0.8 2.6 (0.3 – 9.5)
R03BA Glucocorticoids, 
inhalants
4 0 3.6 1.1 (0.3 – 2.8) 5 0 37 0.1 (0.04 – 0.3)
R03AK Adrenergics and 
other drugs for 
obstructive airway 
diseases
2 0 2.0 1.0 (0.1 – 3.7) 10 1 33 0.3 (0.1 – 0.6)
R05CB Mucolytics 1 0 1.2 0.8 (0.02–4.5) 3 1 28 0.1 (0.02 – 0.3)
R06AE Piperazine 
derivatives
1 0 1.5 0.7 (0.02–3.8) 3 1 19 0.2 (0.03 – 0.5)
R03AC Selective beta-2-
adrenoreceptor 
agonists
2 1 4.4 0.5 (0.1 – 1.7) 5 0 49 0.1 (0.03 – 0.2)
D07AA Corticosteroids. 
weak (group I)
1 0 4.9 0.2 (0.01 – 1.1) 0 0 6.3 0.0 (-0.6)1
D02AX Other emollients 
and protectives
1 0 53 0.02 (0.001 – 0.1) 0 0 149 0 (-0.02)1
ADR, adverse drug reaction; CI, confidence interval; DDD, defined daily dose; ICSR, individual case safety report
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The ADRs reported during treatment with sympathomi-
metics were generally labelled in the SPC, thus known
previously. The only reported ADR not specified in the
SPC was an obsessive reaction, whereas anxiety in general
is mentioned in the SPC.
In hospitalized children, the overall incidence of ADRs
has been reported to be 9.5% and in outpatient patients
the corresponding figure was 1.5% [4]. Hence, the
number of ICSR in the present study indicates that there is
an under-reporting of ADRs not only in adults, as previ-
ously shown [13,14], but also in children. The frequency
of under-reporting in children needs to be further
explored. Furthermore, the present study only allows con-
clusions concerning the paediatric population <15 years
old, whereas children according to European Medicines
Agency include 0 to 17 years.
In the present study, five percent of the ICSRs in children
included serious ADRs. The corresponding figure for
adults was 32%. With vaccine reports included, the pro-
portion of serious ADRs has been reported to be 13% in
children [4].
The design of the present study does not to allow conclu-
sions concerning the question whether the number of
ICSRs per million DDD differs between children and
adults. Lower doses are often used in children, making
direct comparisons difficult. Moreover, dose adjustments
for children compared with DDD may vary depending on
age of the child as well as the drug in question, making
comparisons using DDD as denominator inconclusive.
The number of ICSRs in the present study is quite small,
implying that minor fluctuations in the number of reports
can significantly affect the result. Hence, the disposition
of ADRs in children needs further investigation.
Conclusion
In conclusion, the present study indicates that ADRs are
reported for commonly used drugs in children. The
number of ICSRs varies in different groups of drugs. A
possible signal for montelukast and psychiatric adverse
drug reactions was found, which should be further
explored.
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Table 2: Description of ICSRs for children in the ATC code R03DC. All ICSRs concerned the substance montelukast.
Age (years) Dose (mg/day) Treatment duration 
(when known)
ADR SPC (Yes/No)
44- N i g h t  m a r e s Y e s
3 4 - Sleep disorders Yes
3 4 - Cranial nerve lesion No
4 4 2 years Haemorrhage Yes
Pruritus Yes
Abdominal pain Yes
Rectal pain No
2 4 - Fever No
Fatigue Yes
Rash No
1 4 4 days Anxiety No
34- N i g h t  m a r e s Y e s
Aggressiveness Yes
2 4 4 days Aggressiveness Yes
3 4 continuing Night mares Yes
3 4 2 doses Asthma aggravated No
2 4 11 days Rash No
Pruritus Yes
Sleep disorder Yes
Night mares Yes
1 4 2 weeks Anxiety No
Sleep disorder Yes
6 5 8 weeks Xerophthalmia No
5 4 3 weeks Appetite increased No
8 5 (on demand) 5 weeks Leucopenia No
Red blood cell disorder No
14 10 2 years Arthralgia Yes
Myalgia Yes
ADR, adverse drug reaction; ICSR, individual case safety report; SPC, summary of product characteristicsPublish with BioMed Central    and   every 
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